<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35271698</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1528-0020</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>139</Volume>
            <Issue>17</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Blood</Title>
          <ISOAbbreviation>Blood</ISOAbbreviation>
        </Journal>
        <ArticleTitle>International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.</ArticleTitle>
        <Pagination>
          <StartPage>2601</StartPage>
          <EndPage>2621</EndPage>
          <MedlinePgn>2601-2621</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1182/blood.2021014343</ELocationID>
        <Abstract>
          <AbstractText>Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management of LCH in adults are mostly derived from the pediatric literature. Over the last decade, the discovery of clonality and MAPK-ERK pathway mutations in most cases led to the recognition of LCH as a hematopoietic neoplasm, opening the doors for treatment with targeted therapies. These advances have necessitated an update of the existing recommendations for the diagnosis and treatment of LCH in adults. This document presents consensus recommendations that resulted from the discussions at the annual Histiocyte Society meeting in 2019, encompassing clinical features, classification, diagnostic criteria, treatment algorithm, and response assessment for adults with LCH. The recommendations favor the use of 18F-Fluorodeoxyglucose positron emission tomography-based imaging for staging and response assessment in the majority of cases. Most adults with unifocal disease may be cured by local therapies, while the first-line treatment for single-system pulmonary LCH remains smoking cessation. Among patients not amenable or unresponsive to these treatments and/or have multifocal and multisystem disease, systemic treatments are recommended. Preferred systemic treatments in adults with LCH include cladribine or cytarabine, with the emerging role of targeted (BRAF and MEK inhibitor) therapies. Despite documented responses to treatments, many patients struggle with a high symptom burden from pain, fatigue, and mood disorders that should be acknowledged and managed appropriately.</AbstractText>
          <CopyrightInformation>© 2022 by The American Society of Hematology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Goyal</LastName>
            <ForeName>Gaurav</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-6148-5177</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tazi</LastName>
            <ForeName>Abdellatif</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-0788-7444</Identifier>
            <AffiliationInfo>
              <Affiliation>Université de Paris, INSERM UMR 976, Saint Louis Research Institute, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>French National Reference Center for Histiocytoses, Department of Pulmonology, Saint-Louis Teaching Hospital, Assistance Publique-Hôpiaux de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Go</LastName>
            <ForeName>Ronald S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Divison of Hematology, and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rech</LastName>
            <ForeName>Karen L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Picarsic</LastName>
            <ForeName>Jennifer L</ForeName>
            <Initials>JL</Initials>
            <Identifier Source="ORCID">0000-0002-3718-6422</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vassallo</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pulmonary and Critical Care Medicine, and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Young</LastName>
            <ForeName>Jason R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cox</LastName>
            <ForeName>Christian W</ForeName>
            <Initials>CW</Initials>
            <Identifier Source="ORCID">0000-0003-2807-5824</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Van Laar</LastName>
            <ForeName>Jan</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-8885-4929</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Erasmus University Medical Center, Rotterdam. The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hermiston</LastName>
            <ForeName>Michelle L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Hematology-Oncology, University of California, San Francisco, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Xin-Xin</ForeName>
            <Initials>XX</Initials>
            <Identifier Source="ORCID">0000-0001-7884-3073</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Makras</LastName>
            <ForeName>Polyzois</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-3231-3357</Identifier>
            <AffiliationInfo>
              <Affiliation>LCH Adult Clinic, and.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaltsas</LastName>
            <ForeName>Gregory</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-5876-7883</Identifier>
            <AffiliationInfo>
              <Affiliation>1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haroche</LastName>
            <ForeName>Julien</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Service de médecine interne 2, Centre de Référence des Histiocytoses, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Collin</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Newcastle University and Newcastle Upon Tyne Hospitals, Newcastle Upon Tyne, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McClain</LastName>
            <ForeName>Kenneth L</ForeName>
            <Initials>KL</Initials>
            <Identifier Source="ORCID">0000-0003-0725-6263</Identifier>
            <AffiliationInfo>
              <Affiliation>Texas Children's Cancer and Hematology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diamond</LastName>
            <ForeName>Eli L</ForeName>
            <Initials>EL</Initials>
            <Identifier Source="ORCID">0000-0001-5456-5961</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Girschikofsky</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Internal Medicine I (Hemostasis, Hematology and Stem, Cell Transplantation and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Blood</MedlineTA>
        <NlmUniqueID>7603509</NlmUniqueID>
        <ISSNLinking>0006-4971</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>47M74X9YT5</RegistryNumber>
          <NameOfSubstance UI="D017338">Cladribine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017338" MajorTopicYN="N">Cladribine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006646" MajorTopicYN="Y">Histiocytosis, Langerhans-Cell</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>17</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35271698</ArticleId>
        <ArticleId IdType="doi">10.1182/blood.2021014343</ArticleId>
        <ArticleId IdType="pii">S0006-4971(22)00367-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
